Metastatic colorectal cancer: Treatment strategies with current cytotoxic regimens

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The availability of the cytotoxic agents irinotecan, oxaliplatin, and capecitabine and the targeted biologic agents bevacizumab and cetuximab has dramatically expanded treatment options for patients with metastatic colorectal cancer (mCRC). These agents signaled a new era in the management of mCRC and the possibility of improved outcomes for many patients. In the past, 5-fluorouracil (5-FU) alone or in combination with leucovorin (LV) was the only treatment available for patients with mCRC. Currently, at least five first-line therapies, nine second-line therapies, six third-line therapies, and one fourth-line therapy are available for these patients. No single regimen has emerged as a standard of care for mCRC, challenging oncologists to develop a treatment plan that includes the best integration and sequencing of agents for each patient. Key trials show that both irinotecan and oxaliplatin, when given with infusional 5-FU/LV, are appropriate first-line combination chemotherapy regimens for patients with mCRC. Evidence is also accumulating that exposure to all three cytotoxic agents (5-FU/LV, irinotecan, and oxaliplatin) over the course of treatment can optimize outcomes. Choice of first-line therapy must be based on parameters that include treatment tolerability and impact on later lines of therapy.

Original languageEnglish (US)
Pages (from-to)5-11
Number of pages7
JournalCommunity Oncology
Volume3
Issue number6 SUPPL. 2
StatePublished - Jun 2006

Fingerprint

Colorectal Neoplasms
oxaliplatin
irinotecan
Leucovorin
Therapeutics
Fluorouracil
Cytotoxins
Biological Factors
Proxy
Standard of Care
Combination Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Metastatic colorectal cancer : Treatment strategies with current cytotoxic regimens. / Blanke, Charles.

In: Community Oncology, Vol. 3, No. 6 SUPPL. 2, 06.2006, p. 5-11.

Research output: Contribution to journalArticle

@article{8d9676b9c1344c35803dee0de47c1c92,
title = "Metastatic colorectal cancer: Treatment strategies with current cytotoxic regimens",
abstract = "The availability of the cytotoxic agents irinotecan, oxaliplatin, and capecitabine and the targeted biologic agents bevacizumab and cetuximab has dramatically expanded treatment options for patients with metastatic colorectal cancer (mCRC). These agents signaled a new era in the management of mCRC and the possibility of improved outcomes for many patients. In the past, 5-fluorouracil (5-FU) alone or in combination with leucovorin (LV) was the only treatment available for patients with mCRC. Currently, at least five first-line therapies, nine second-line therapies, six third-line therapies, and one fourth-line therapy are available for these patients. No single regimen has emerged as a standard of care for mCRC, challenging oncologists to develop a treatment plan that includes the best integration and sequencing of agents for each patient. Key trials show that both irinotecan and oxaliplatin, when given with infusional 5-FU/LV, are appropriate first-line combination chemotherapy regimens for patients with mCRC. Evidence is also accumulating that exposure to all three cytotoxic agents (5-FU/LV, irinotecan, and oxaliplatin) over the course of treatment can optimize outcomes. Choice of first-line therapy must be based on parameters that include treatment tolerability and impact on later lines of therapy.",
author = "Charles Blanke",
year = "2006",
month = "6",
language = "English (US)",
volume = "3",
pages = "5--11",
journal = "Community Oncology",
issn = "1548-5315",
publisher = "BioLink Communications",
number = "6 SUPPL. 2",

}

TY - JOUR

T1 - Metastatic colorectal cancer

T2 - Treatment strategies with current cytotoxic regimens

AU - Blanke, Charles

PY - 2006/6

Y1 - 2006/6

N2 - The availability of the cytotoxic agents irinotecan, oxaliplatin, and capecitabine and the targeted biologic agents bevacizumab and cetuximab has dramatically expanded treatment options for patients with metastatic colorectal cancer (mCRC). These agents signaled a new era in the management of mCRC and the possibility of improved outcomes for many patients. In the past, 5-fluorouracil (5-FU) alone or in combination with leucovorin (LV) was the only treatment available for patients with mCRC. Currently, at least five first-line therapies, nine second-line therapies, six third-line therapies, and one fourth-line therapy are available for these patients. No single regimen has emerged as a standard of care for mCRC, challenging oncologists to develop a treatment plan that includes the best integration and sequencing of agents for each patient. Key trials show that both irinotecan and oxaliplatin, when given with infusional 5-FU/LV, are appropriate first-line combination chemotherapy regimens for patients with mCRC. Evidence is also accumulating that exposure to all three cytotoxic agents (5-FU/LV, irinotecan, and oxaliplatin) over the course of treatment can optimize outcomes. Choice of first-line therapy must be based on parameters that include treatment tolerability and impact on later lines of therapy.

AB - The availability of the cytotoxic agents irinotecan, oxaliplatin, and capecitabine and the targeted biologic agents bevacizumab and cetuximab has dramatically expanded treatment options for patients with metastatic colorectal cancer (mCRC). These agents signaled a new era in the management of mCRC and the possibility of improved outcomes for many patients. In the past, 5-fluorouracil (5-FU) alone or in combination with leucovorin (LV) was the only treatment available for patients with mCRC. Currently, at least five first-line therapies, nine second-line therapies, six third-line therapies, and one fourth-line therapy are available for these patients. No single regimen has emerged as a standard of care for mCRC, challenging oncologists to develop a treatment plan that includes the best integration and sequencing of agents for each patient. Key trials show that both irinotecan and oxaliplatin, when given with infusional 5-FU/LV, are appropriate first-line combination chemotherapy regimens for patients with mCRC. Evidence is also accumulating that exposure to all three cytotoxic agents (5-FU/LV, irinotecan, and oxaliplatin) over the course of treatment can optimize outcomes. Choice of first-line therapy must be based on parameters that include treatment tolerability and impact on later lines of therapy.

UR - http://www.scopus.com/inward/record.url?scp=33746930285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746930285&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33746930285

VL - 3

SP - 5

EP - 11

JO - Community Oncology

JF - Community Oncology

SN - 1548-5315

IS - 6 SUPPL. 2

ER -